Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Strategic Asset Allocation Index
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Strategic Asset Allocation Index of 21.7% as of September 2023. Strategic assets (PP&E of CN¥1.01 Billion plus long-term investments of CN¥-) total CN¥1.01 Billion, measured against net assets of CN¥4.64 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Tianjin Lisheng Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Tianjin Lisheng Pharmaceutical Co Ltd Strategic Asset Allocation Index (2007–2021)
This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 15 annual periods from 2007 to 2021. As of September 2023, the index stands at 21.7%, representing strategic assets of CN¥1.01 Billion against net assets of CN¥4.64 Billion CNY. See financial flexibility index of Tianjin Lisheng Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2021, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Tianjin Lisheng Pharmaceutical Co Ltd.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 25.8% | CN¥1.14 Billion | CN¥1.14 Billion | CN¥- | CN¥4.41 Billion | ▲ +0.5 pp |
| 2020 | 25.3% | CN¥1.09 Billion | CN¥1.09 Billion | CN¥- | CN¥4.30 Billion | ▲ +0.1 pp |
| 2019 | 25.2% | CN¥1.11 Billion | CN¥1.11 Billion | CN¥- | CN¥4.42 Billion | ▼ -18.9 pp |
| 2018 | 44.2% | CN¥1.42 Billion | CN¥1.12 Billion | CN¥294.11 Million | CN¥3.21 Billion | ▲ +7.4 pp |
| 2017 | 36.7% | CN¥1.13 Billion | CN¥1.13 Billion | CN¥- | CN¥3.08 Billion | ▼ -27.9 pp |
| 2016 | 64.6% | CN¥1.95 Billion | CN¥1.64 Billion | CN¥305.91 Million | CN¥3.02 Billion | ▲ +4.5 pp |
| 2015 | 60.2% | CN¥1.79 Billion | CN¥1.55 Billion | CN¥232.18 Million | CN¥2.97 Billion | ▲ +16.7 pp |
| 2014 | 43.5% | CN¥1.27 Billion | CN¥1.27 Billion | CN¥- | CN¥2.91 Billion | ▲ +8.7 pp |
| 2013 | 34.8% | CN¥1.02 Billion | CN¥1.02 Billion | CN¥- | CN¥2.92 Billion | ▲ +10.2 pp |
| 2012 | 24.5% | CN¥683.97 Million | CN¥683.97 Million | CN¥- | CN¥2.79 Billion | ▲ +11.0 pp |
| 2011 | 13.5% | CN¥378.02 Million | CN¥378.02 Million | CN¥- | CN¥2.80 Billion | ▲ +2.4 pp |
| 2010 | 11.1% | CN¥295.02 Million | CN¥295.02 Million | CN¥- | CN¥2.65 Billion | ▼ -45.7 pp |
| 2009 | 56.8% | CN¥267.67 Million | CN¥267.67 Million | CN¥- | CN¥470.87 Million | ▲ +22.4 pp |
| 2008 | 34.4% | CN¥163.37 Million | CN¥163.37 Million | CN¥- | CN¥474.77 Million | ▼ -2.7 pp |
| 2007 | 37.1% | CN¥160.41 Million | CN¥160.41 Million | CN¥- | CN¥432.23 Million | — |